Fig. 3

CENPA was closely related to clinical traits and overexpressed in ccRCC tissues and cells. Public datasets showed CENPA overexpression in ccRCC compared to normal tissues. A In TCGA-KIRC cohort, 533 ccRCC samples showed higher CENPA expression than 72 normal samples. For tissues gathered from the same patients, CENPA overexpressed in cancer tissues compared to cancer-adjacent tissues in B TCGA-KIRC dataset (72 pairs of samples), C GSE40435 dataset (101 pairs of samples), D GSE66272 dataset (26 pairs of samples) and E Jones Renal dataset (23 pairs of samples). The expression of CENPA elevated with various clinicopathological factors in public datasets, including F, J T stage (528 samples in TCGA-KIRC and 26 samples in GSE66272), G AJCC clinical stage (527 samples in TCGA-KIRC), and H, I, K G grade (522 samples in TCGA-KIRC, 101 samples in GSE40435 and 26 samples in GSE66272). L The ROC curve of CENPA expression (AUC = 0.9651; p < 0.0001) in TCGA-KIRC cohort. Our own cohort validated CENPA overexpression in ccRCC through M qRT-PCR assays (42 pairs), N immunoblotting tests (12 pairs), and O immunohistochemical analyses (2 pairs). CENPA overexpressed in renal cancer cell lines (786-O, A498, ACHN, Caki-1 and OSRC-2) compared to normal renal cell line (HK-2) via P qRT-PCR and Q immunoblotting tests. Relative *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Error bars indicate mean ± SD. AUC: areas under the curve